Loading...
XHKG
1873
Market cap471mUSD
Jun 06, Last price  
1.78HKD
1D
1.71%
1Q
28.99%
IPO
-64.61%
Name

VIVA Biotech Holdings

Chart & Performance

D1W1MN
P/E
20.28
P/S
1.71
EPS
0.08
Div Yield, %
Shrs. gr., 5y
14.07%
Rev. gr., 5y
43.80%
Revenues
1.99b
-7.84%
96,492,000148,245,000210,033,000323,057,000696,958,0002,104,083,0002,379,631,0002,155,578,0001,986,651,000
Net income
167m
P
24,473,00076,260,00090,550,000265,872,000-386,880,000287,546,000-528,475,000-116,113,000167,294,000
CFO
0k
-100.00%
21,118,00027,891,00012,110,00046,012,00043,181,00077,830,000386,051,000383,405,0000
Dividend
Jun 16, 20210.01 HKD/sh
Earnings
Jun 26, 2025

Profile

Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure determination of protein, and SPR technology. It also provides cell lines, crystal structures, GPCR proteins, antibodies, and proteins. In addition, the company offers contract development and manufacturing services for small molecule active pharmaceutical ingredients (APIs) and intermediates; and trades in APIs, intermediates, and formulations, as well as equity for service. Further, it provides research service; laboratory rental services; and project management and bidding services, as well as sells compounds. The company was incorporated in 2008 and is headquartered in Shanghai, China.
IPO date
May 09, 2019
Employees
2,271
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
1,986,651
-7.84%
2,155,578
-9.42%
2,379,631
13.10%
Cost of revenue
1,751,360
1,954,769
2,104,240
Unusual Expense (Income)
NOPBT
235,291
200,809
275,391
NOPBT Margin
11.84%
9.32%
11.57%
Operating Taxes
73,718
43,837
45,055
Tax Rate
31.33%
21.83%
16.36%
NOPAT
161,573
156,972
230,336
Net income
167,294
-244.08%
(116,113)
-78.03%
(528,475)
-283.79%
Dividends
Dividend yield
Proceeds from repurchase of equity
(10,274)
BB yield
0.48%
Debt
Debt current
552,484
952,441
1,916,180
Long-term debt
760,307
982,469
909,030
Deferred revenue
73,123
Other long-term liabilities
1,376,151
1,277,046
(165,324)
Net debt
(617,339)
(139,596)
1,100,025
Cash flow
Cash from operating activities
383,405
386,051
CAPEX
(187,678)
(249,328)
Cash from investing activities
439,174
(372,804)
Cash from financing activities
(429,502)
(143,196)
FCF
310,431
491,191
7,975
Balance
Cash
941,581
1,036,322
678,569
Long term investments
988,549
1,038,184
1,046,616
Excess cash
1,830,797
1,966,727
1,606,203
Stockholders' equity
3,973,891
(51,605)
102,415
Invested Capital
4,645,626
6,919,780
6,913,867
ROIC
2.79%
2.27%
3.37%
ROCE
3.63%
2.92%
3.87%
EV
Common stock shares outstanding
2,868,364
2,028,679
1,915,437
Price
0.86
-18.10%
1.05
-40.00%
1.75
-62.85%
Market cap
2,466,793
15.81%
2,130,113
-36.45%
3,352,015
-63.89%
EV
1,863,298
1,990,517
4,452,040
EBITDA
235,291
412,025
460,845
EV/EBITDA
7.92
4.83
9.66
Interest
176,582
184,674
Interest/NOPBT
87.94%
67.06%